Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus NYSTEX.
MYHIBBIN vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal